Annovis Bio, Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 52/100
What the filing says
On November 3, 2026, Annovis Bio stockholders approved an amendment to the Certificate of Incorporation increasing total authorized shares to 142M (140M common at $0.0001 par, 2M preferred at $0.0001 par). The amendment was filed with Delaware on November 4, 2026. No prior authorization levels or current outstanding share counts are disclosed in this filing.
Why this rating
Share authorization increase is standard corporate maintenance; significance moderate given lack of disclosed context on prior authorization or dilution risk relative to $36.1M market cap.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.